Anti-TIGIT antibodies and methods of use
US-10047158-B2 · Aug 14, 2018 · US
Antiviral immunotherapy by membrane receptor ligation
US11208469B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11208469-B2 |
| Application number | US-201816131325-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 14, 2018 |
| Priority date | Mar 18, 2016 |
| Publication date | Dec 28, 2021 |
| Grant date | Dec 28, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a cytotoxic agent for the prophylaxis and/or treatment of a viral infection which is configured for the selective binding to a membrane receptor of virus-infected T lymphocytes, a pharmaceutical composition containing said cytotoxic agent, the use of the cytotoxic agent for the prophylaxis and/or treatment of viral infections, a method of finding cytotoxic agents, the use of a membrane receptor of virus-infected T lymphocytes which is overexpressed in comparison to non-infected T lymphocytes for the diagnosis of a viral infection.
First claim
Opening claim text (preview).
What is claimed is: 1. A cytotoxic agent for the treatment of an HIV viral infection, which is configured for the selective binding to a membrane receptor of virus infected CD4 + T lymphocytes, wherein the membrane receptor is CD134, the cytotoxic agent virostatic or a cytostatic agent, wherein the cytostatic agent is selected from the group consisting of an alkylating agent, a platinum analogue, an intercalant, a mitosis inhibitor, and a taxane, and the cytotoxic agent is coupled to an agonistic antibody that selectively binds to CD134. 2. The cytotoxic agent of claim 1 , wherein the agonistic antibody is selected from the group consisting of: MEDI6469 (9B12), MEDI6383, MEDI0562, Hu106-222 and Hu119-122 (UTMDACC). 3. A pharmaceutical composition comprising the cytotoxic agent of claim 1 and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
- C07K16/114Primary
Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title
- C07K16/2878Primary
against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title
Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title
Agonist effect on antigen · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11208469B2 cover?
- The present invention relates to a cytotoxic agent for the prophylaxis and/or treatment of a viral infection which is configured for the selective binding to a membrane receptor of virus-infected T lymphocytes, a pharmaceutical composition containing said cytotoxic agent, the use of the cytotoxic agent for the prophylaxis and/or treatment of viral infections, a method of finding cytotoxic agent…
- Who is the assignee on this patent?
- Univ Tuebingen Medizinische Fakultaet
- What technology area does this patent fall under?
- Primary CPC classification C07K16/114. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).